Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Ultragenyx Pharma (RARE) Tops Q4 EPS by 6c, Revenues Beat
February 19, 2019 4:05 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.73), $0.06 better than the analyst estimate of ($1.79). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $13.65 million.
This last year was important for Ultragenyx as we successfully launched two therapies internationally and... More
